FDA has approved six extended-release/long-acting opioid analgesic products with labeling that describes studies conducted to support abuse-deterrent properties.
There are no immediate-release single-entity or combination opioid products labeled with abuse-deterrent claims pursuant to the agency's April 2015 final...